Supplementary Materials Supplementary methods: Description of the LDCT screening cohorts participating in this study

PanCan: Pan-Canadian Early Detection of Lung Cancer Study

This study prospectively recruited 2537 subjects between September 2008, and December, 2010 [1]. Participants had at least a 2% 6-year risk of lung cancer as estimated by the PanCan model, a precursor to the validated PLCOm2012 model. The eligible subjects were ever smokers, aged 50-75 years who had no previous history of invasive cancer. The subjects were recruited at eight centers across Canada (Vancouver, Calgary, Hamilton, Toronto, Ottawa, Quebec, Halifax, and St. John's). All study participants completed a detailed questionnaire, spirometry, collection of blood specimens for biomarker measurement and LDCT at baseline. Participants with abnormal LDCT results (the presence of any noncalcified non-perifissural pulmonary nodule or a nodule with non-solid area of at least 1mm diameter) were followed up every 3-24 months. A nodule was considered benign if it showed a benign calcification pattern (e.g., fully calcified, popcorn calcification) or if the size and density of was unchanged for longer than 2 years.

UKLS: The UK Lung Cancer Pilot Screening Trial

The UKLS is a randomized controlled trial of LDCT screening in individuals aged 50-75 years with at least 4.5% risk of developing lung cancer in 5 years based on the Liverpool Lung Project (LLPv2) risk model [2, 3]. The subjects with any comorbidity that unequivocally contraindicated either screening or treatment were excluded. There were 4055 individuals recruited in two geographical areas, covering six primary care trusts around Liverpool and Cambridge, from 2011 to 2013. The participants were randomized to receive either LDCT or usual care, 1994 of which underwent LDCT scans. Most participants had their lung function measured, provided blood samples, and completed detailed epidemiological, psychosocial and health economics questionnaires at baseline. The LDCT subjects received a baseline scan and nodules

were assessed by two local radiologists and placed in one of four pre-defined nodule categories: Category 4 (Solid: volume >500mm³ or diameter >10mm; Part solid: solid component- volume >500mm³); Category 3 (Solid: volume 50 - 500mm³ or diameter 5 - 9.9mm; Part solid: non-solid component diameter >5mm, solid component :15 - 500mm³ or diameter 3 - 9.9mm; Non-solid: diameter ≥ 5mm), Category 2 (Solid: volume 15 - 49mm³ or diameter 3 -4.9mm; Part solid: solid component volume <15mm³ or diameter < 3mm; Non solid diameter 3 - 4.9mm); Category 1 (Benign nodule or volume <15mm³ or diameter <3mm or features of an intrapulmonary lymph node). Consensus nodule category was assigned following central reading at the Royal Brompton Hospital, with a read for arbitration when necessary. Category 4 nodules were immediately referred for work-up and clinical management. Category 3 nodules identified in the baseline scan were re-analyzed in follow-up CT scans at three and twelve months; Category 2 nodules at twelve months only. Category 1 nodules were considered normal and had no further follow-up. Growth of nodules was based on their characteristics and volume doubling time (VDT); i.e. VDT <400 days or new solid component of non-solid nodule was classified as growth in the UKLS trial and were referred to the trial participating MDT clinic for work-up and clinical management.

IELCAP-Toronto: International Early Lung Cancer Action Program – Toronto

This single arm early detection of lung cancer research study at Princess Margaret Cancer Centre, Toronto, Canada joined the international Early Lung Cancer Action Program (I-ELCAP) in 2003 [4, 5]. Ever smokers of more than 10 pack-years, aged 50 years or older were eligible for LDCT screening. A total of 4782 individuals have been enrolled in the Greater Toronto Area, and 4161 of those have the clinicepidemiological data needed to be part of INTEGRAL. Participants were administered a LDCT scan along with a standard study questionnaire at baseline. Blood samples were systematically collected at baseline since 2006. In this study, a LDCT results was considered to be normal if no nodules of the size of 5 mm or larger was found. In case of a positive LDCT result, an indeterminate noncalcified solid or part-solid nodule 5 mm or larger, or a nonsolid nodule 8 mm or larger was detected. The abnormal scans were followed up at 1-2 years depending on nodule size and shape. The location, size, consistency, calcifications and spiculations were determined for each nodule.

P-IELCAP: Pamplona International Early Lung Cancer Action Program

P-IELCAP is an ongoing lung cancer screening program in Spain which began recruitment in September 2000 [6]. It is part of the I-ELCAP consortium. As of December 2019, the program had enrolled 3825 asymptomatic subjects older than 40 years of age, including former of current smokers (\geq 10 pack-years), cancer-free 5 years prior to enrollment. The subjects completed LDCT, spirometry, blood collection and a health questionnaire at baseline and during follow up. Subjects with a positive baseline LDCT (noncalcified nodules \geq 5 or 6 mm depending on the year of enrollment), had imaging follow up at 1-3 months. Subjects with negative scans or small pulmonary nodules at baseline had follow up LDCTs at annual intervals.

Supplementary Table 2: Summary of the top 11 informative circulating protein markers

Gene name	Full name (Ensembl Gene ID)	Cytoband	Expression in selected tissues focuses on lung and immune system			
			Normal tissues: Human Protein Atlas (HPA) [7]and Proteomics DB (PDB) [8-10]		Cancer tissues: Human Protein Atlas (HPA)[7]	
			Protein expression	mRNA expression- HPA	Protein	mRNA
WFDC2	WAP four-disulfide core domain 2 (ENSG00000101443)	20q13	HPA: Bronchus ^H PDB: Lung	Lung	Lung cancer	Lung cancer
FASLG	Fas ligand (ENSG00000117560)	1q24	HPA: Bone marrow ^M , Lymph node ^L PDB: Data not available	Lymph node, Lung	No expression	Lung cancer
CXCL17	C-X-C motif chemokine ligand 17 (ENSG00000189377)	19q13	HPA: Data not available PDB: Lung	Lung	Data not available	Lung cancer
TSHB	Thyroid stimulating hormone subunit beta (ENSG00000134200)	1q13	HPA: None PDB: None	Lung	No expression	Lung cancer
TRAIL-R2 (TNFRSF10B)	TNF receptor superfamily member 10b (ENSG00000120889)	8p21	HPA: Bronchus ^H , Lung ^H , Lymph node ^M PDB: Lung, Blood platelet	Lung, Bone marrow, Lymph node	Lung cancer	Lung cancer, Blood platelet
SCGB3A2	Secretoglobin family 3a member 2 (ENSG00000164265)	5q32	HPA: Data not available PDB: Lung	Lung	Data not available	Lung cancer
FCRL5	Fc receptor like 5 (ENSG00000143297)	1q23	HPA: Data not available PDB: Lung	Lymph node, Bone marrow, Lung	Data not available	Lung cancer

KRT19	Keratin 19 (ENSG00000171345)	17q21	<u>HPA:</u> Bronchus ^H , Lung ^H <u>PDB:</u> Lung, Lymph node, Cytotoxic T-lymphocyte, Blood platelet	Lung	Lung cancer	Lung cancer
KPNA1	Karyopherin subunit alpha 1 (ENSG00000114030)	3q21	HPA: Lung ^L , Lymph node ^L <u>PDB:</u> Natural killer cell, B- lymphocyte, Cytotoxic T- lymphocyte, Monocyte, Lymph node, Lung, Helper T-lymphocyte, Cardia, Blood platelet	Lymph node, Lung	Lung cancer	Lung cancer
MMP12	Matrix metallopeptidase 12 (ENSG00000262406)	11q22	HPA: Data not available PDB: Lymph node, Lung, Bone marrow, Blood platelet	Lymph node, Lung	Data not available	Lung cancer
CEACAM5	Cea cell adhesion molecule 5 (ENSG0000105388)	19q13	HPA: Lung ^L , Bone marrow ^L PDB: Lung	Lung	Lung cancer	Lung cancer

ProteomicsDB (PDB)

Supplementary Figure 1: Forest plots of the top circulating protein markers illustrating the association with nodule malignancy stratified by study site, time to diagnosis, smoking status, sex, histology and nodule size, after adjustment for Brock score. The Odds Ratios (OR) and the 95% Confidence Intervals (CI) are presented.

	WFDC2			FASLG	
Subgroup		OR (95% CI) P-value	Subgroup		OR (95% CI) P-value
Study Site PanCan IELCAP-Toronto Spain UKLS		1.54(1.17-2.06)<0.01 1.63(1.15-2.36)<0.01 1.43(0.94-2.22) 0.10 1.33(0.95-1.90) 0.10	Study Site PanCan IELCAP-Toronto Spain UKLS		0.80 (0.62 - 1.03) 0.08 1.02 (0.74 - 1.41) 0.88 0.59 (0.39 - 0.87) <0.01 0.72 (0.53 - 0.97) 0.03
Time to Diagnosis <1year 1year-3years >3years Smoking Status Former smokers		1.58 (1.21 - 2.08) <0.01 1.29 (1.04 - 1.61) 0.02 1.61 (1.23 - 2.12) <0.01 1.21 (0.94 - 1.56) 0.15	Time to Diagnosis <1year 1year-3years >3years Smoking Status Former smokers		0.74 (0.58 - 0.93) 0.01 0.73 (0.60 - 0.89) <0.01 0.87 (0.68 - 1.12) 0.29 0.86 (0.68 - 1.09) 0.22
Current smokers Sex Male Female		1.66 (1.30 - 2.13) <0.01 1.50 (1.21 - 1.87) <0.01 1.44 (1.10 - 1.89) <0.01	Current smokers Sex Male Female		0.74 (0.60 - 0.91) <0.01 0.71 (0.57 - 0.86) <0.01 0.88 (0.69 - 1.12) 0.30
Histology Adenocarcinoma Squamous cell Small cell		1.40 (1.13 - 1.73) <0.01 1.91 (1.38 - 2.69) <0.01 1.87 (1.23 - 2.88) <0.01	Histology Adenocarcinoma Squamous cell Small cell		0.87 (0.72 - 1.06) 0.17 0.66 (0.49 - 0.88) <0.01 0.62 (0.41 - 0.92) 0.02
Nodule Size <= 6 mm > 6 mm		1.81 (1.33 - 2.50) <0.01 1.30 (1.04 - 1.63) 0.02	Nodule Size <= 6 mm > 6 mm		0.80 (0.59 - 1.07) 0.14 0.80 (0.65 - 0.98) 0.03
Overall 0.50	1.0 1.5 2.0 OR & 95% CI	1.49 (1.26 - 1.76) <0.01	Overall	0.50 1.0 1.5 2.0 OR & 95% CI	0.77 (0.66 - 0.90) <0.01

CXL17 TSHB Subgroup OR (95% CI) P-value Subgroup OR (95% CI) P-value **Study Site Study Site** PanCan 1.41 (1.04 - 1.92) 0.03 PanCan 0.77 (0.58 - 1.01) 0.07 **IELCAP-Toronto** 1.87 (1.29 - 2.80) < 0.01 **IELCAP-Toronto** 0.84 (0.60 - 1.18) 0.32 1.22 (0.78 - 1.90) 0.39 0.61(0.38-0.91) 0.02 Spain Spain UKLS UKLS 1.26 (0.87 - 1.84) 0.23 0.79 (0.57 - 1.08) 0.16 Time to Diagnosis **Time to Diagnosis** <1year <1year 1.29(0.99-1.70) 0.06 0.76 (0.59 - 0.98) 0.03 1year-3years 1year-3years 1.41 (1.12 - 1.78) < 0.01 0.72 (0.58 - 0.88) < 0.01 >3years 0.93 (0.73 - 1.18) 0.56 1.52 (1.14 - 2.03) < 0.01 >3years **Smoking Status Smoking Status** Former smokers 1.55 (1.08 - 2.24) 0.02 Former smokers 0.88 (0.70 - 1.10) 0.26 Current smokers Current smokers 1.24 (0.97 - 1.60) 0.09 0.69 (0.55 - 0.87) < 0.01 Sex Sex Male 1.46 (1.16 - 1.85) < 0.01 Male 0.81 (0.65 - 0.99) 0.05 Female 1.36 (1.03 - 1.81) 0.03 0.75 (0.58 - 0.96) 0.02 Female Histology Histology Adenocarcinoma 1.46 (1.17 - 1.83) < 0.01 Adenocarcinoma 0.85 (0.70 - 1.02) 0.09 Squamous cell Squamous cell 1.28(0.91-1.81) 0.16 0.81 (0.60 - 1.08) 0.15 Small cell 1.81 (1.15 - 2.86) 0.01 Small cell 0.74 (0.50 - 1.10) 0.13 **Nodule Size** Nodule Size <= 6 mm 1.50 (1.08 - 2.10) 0.02 $< = 6 \, \text{mm}$ 0.81 (0.60 - 1.11) 0.19 > 6 mm 1.39 (1.10 - 1.77) <0.01 > 6 mm 0.76(0.61-0.94) 0.01 Overall 1.42 (1.19 - 1.70) < 0.01 Overall 0.78 (0.66 - 0.91) < 0.01 0.50 1.0 1.5 2.0 0.50 1.0 1.5 2.0

OR & 95% CI

OR & 95% CI

TRAIL-R2

SCGB3A2

Subgroup		OR (95% CI) P-value	Subgroup	OR (95% CI) P-value
Study Site PanCan IELCAP-Toronto Spain UKLS		1.41 (1.08 - 1.86) 0.01 1.52 (1.00 - 2.88) 0.15 1.25 (0.84 - 1.94) 0.28 1.93 (1.23 - 3.19) <0.01	Study Site PanCan IELCAP-Toronto Spain UKLS	<pre>1.15(0.87-1.51) 0.33 → 1.67(1.20-2.44)<0.01 1.16(0.78-1.73) 0.47 1.32(0.98-1.80) 0.07</pre>
Time to Diagnosis <1year 1year-3years >3years		1.56 (1.19 - 2.07) <0.01 1.30 (1.06 - 1.62) 0.02 1.61 (1.22 - 2.17) <0.01	Time to Diagnosis	1.21(0.96-1.53) 0.11 1.19(0.98-1.44) 0.07 1.46(1.17-1.82)<0.01
Smoking Status Former smokers Current smokers		1.25 (0.98 - 1.67) 0.10 1.55 (1.22 - 2.00) <0.01	Smoking Status Former smokers Current smokers	1.15 (0.86 - 1.56) 0.34 1.28 (1.04 - 1.59) 0.02
Sex Male Female	B	1.66(1.31-2.13)<0.01 1.21(0.95-1.61) 0.15	Sex Male Female	1.29(1.06-1.58) 0.01 1.35(1.05-1.74) 0.02
Histology Adenocarcinoma Squamous cell Small cell	_	1.45(1.17-1.81)<0.01 1.79(1.32-2.49)<0.01 1.64(1.04-2.53)0.03	Histology Adenocarcinoma Squamous cell Small cell	1.32 (1.10 - 1.58) <0.01 1.04 (0.77 - 1.40) 0.78 1.41 (0.98 - 1.97) 0.05
Nodule Size <= 6 mm > 6 mm	• _•	1.78(1.27-2.56)<0.01 1.31(1.06-1.66) 0.02	Nodule Size <= 6 mm	→ 1.60 (1.20 - 2.16) <0.01 1.13 (0.92 - 1.39) 0.24
Overall	0.50 1.0 1.5 2.0 OR & 95% CI	1.46 (1.22 - 1.76) <0.01	Overall 0.50 1.0 1.5 2 OR & 95% CI	1.30 (1.12 - 1.52) <0.01 2.0

FCRL5

KRT19

Subgroup		OR (95% CI) P-value	Subgroup	OR (95% CI) P-value
Study Site PanCan IELCAP-Toronto Spain UKLS		0.98 (0.75 - 1.26) 0.86 0.79 (0.57 - 1.09) 0.16 0.67 (0.43 - 1.03) 0.07 1.01 (0.75 - 1.36) 0.97	Study Site PanCan IELCAP-Toronto Spain UKLS	1.18 (0.91 - 1.55) 0.22 → 1.58 (1.10 - 2.33) 0.02 → 1.35 (0.83 - 2.25) 0.23 → 1.58 (1.12 - 2.27) 0.01
Time to Diagnosis <1year 1year-3years >3years		1.00 (0.80 - 1.25) 0.98 0.78 (0.64 - 0.95) 0.02 0.93 (0.71 - 1.20) 0.57	Time to Diagnosis <1year 1year-3years >3years	➡ 1.84 (1.43 - 2.38) <0.01 1.12 (0.90 - 1.39) 0.31 1.13 (0.86 - 1.49) 0.37
Smoking Status Former smokers Current smokers		0.83(0.64-1.06) 0.13 0.92(0.76-1.12) 0.41	Smoking Status Former smokers Current smokers	1.25 (0.98 - 1.59) 0.07 - 1.49 (1.17 - 1.91) <0.01
Sex Male Female		0.86(0.71-1.04) 0.11 0.85(0.64-1.11) 0.23	Sex Male Female	→ 1.69 (1.35 - 2.15) <0.01 1.03 (0.79 - 1.33) 0.84
Histology Adenocarcinoma Squamous cell Small cell	_	0.79(0.65-0.96) 0.02 1.24(0.94-1.65) 0.13 0.81(0.53-1.23) 0.34	Histology Adenocarcinoma Squamous cell Small cell	1.18 (0.96 - 1.45) 0.12 → 1.68 (1.25 - 2.26) <0.01 - 1.27 (0.82 - 1.88) 0.26
Nodule Size <= 6 mm > 6 mm		0.74(0.53-1.01) 0.07 0.91(0.75-1.11) 0.36	Nodule Size <= 6 mm	1.30(0.96-1.77) 0.09 1.26(1.00-1.60) 0.05
Overall	0.50 1.0 1.5 2.0 OR & 95% CI	0.88(0.76-1.02) 0.09	Overall 0.50 1.0 1.5 OR & 95% CI	1.37 (1.16 - 1.63) <0.01 2.0

KPNA1


MMP12


Subgroup		OR (95% CI) P-value	Subgroup		OR (95% CI) P-value
Study Site PanCan IELCAP-Toronto Spain UKLS		0.71 (0.52 - 0.94) 0.02 0.78 (0.51 - 1.12) 0.21 0.83 (0.52 - 1.19) 0.39 0.73 (0.50 - 1.03) 0.09	Study Site PanCan IELCAP-Toronto Spain UKLS		1.55 (1.19 - 2.06) <0.01 1.22 (0.87 - 1.72) 0.25 1.22 (0.83 - 1.82) 0.31 1.35 (0.98 - 1.88) 0.07
Time to Diagnosis <1year 1year-3years >3years		0.79(0.61-1.03) 0.09 0.69(0.52-0.88)<0.01 0.79(0.58-1.03) 0.12	Time to Diagnosis <1year 1year-3years >3years	,	1.60 (1.27 - 2.04) <0.01 1.14 (0.92 - 1.41) 0.23 1.32 (1.03 - 1.71) 0.03
Smoking Status Former smokers Current smokers	· · · · · · · · · · · · · · · · · · ·	0.65(0.47-0.85)<0.01 0.83(0.66-1.02) 0.10	Smoking Status Former smokers Current smokers		1.04 (0.81 - 1.33) 0.76 1.56 (1.26 - 1.95) <0.01
Sex Male Female		0.67(0.52-0.84)<0.01 0.83(0.62-1.07) 0.18	Sex Male Female	_	1.51(1.24-1.85)<0.01 1.07(0.82-1.40) 0.63
Histology Adenocarcinoma Squamous cell Small cell	← ●	0.78(0.61-0.96) 0.03 0.67(0.45-0.94) 0.03 1.00(0.68-1.32) 1.00	Histology Adenocarcinoma Squamous cell Small cell		1.16 (0.96 - 1.41) 0.13 1.82 (1.35 - 2.49) <0.01 2.12 (1.47 - 3.08) <0.01
Nodule Size <= 6 mm > 6 mm		0.77 (0.53 - 1.03) 0.12 0.73 (0.57 - 0.92) 0.01	Nodule Size <= 6 mm > 6 mm	_	1.56(1.16-2.12)<0.01 1.25(1.02-1.55) 0.03
Overall	0.50 1.0 1.5 2.0 OR & 95% CI	0.73 (0.61 - 0.87) <0.01	0.50	1.0 1.5 2.0 OR & 95% Cl	1.35 (1.16 - 1.58) <0.01

CEACAM5

Subgroup			OR (95% CI) P-value
Study Site PanCan IELCAP-Toronto Spain UKLS			1.20(0.92-1.59) 0.19 1.23(0.91-1.70) 0.19 1.10(0.77-1.61) 0.61 1.13(0.83-1.58) 0.47
Time to Diagnosis <1year 1year-3years >3years			1.43 (1.13 - 1.83) <0.01 1.01 (0.82 - 1.24) 0.93 1.22 (0.95 - 1.58) 0.12
Smoking Status Former smokers Current smokers			1.12(0.86-1.48) 0.42 1.10(0.91-1.35) 0.34
Sex Male Female			1.21(0.99-1.51) 0.08 1.16(0.92-1.48) 0.22
Histology Adenocarcinoma Squamous cell Small cell			1.21 (1.00 - 1.46) 0.05 1.11 (0.82 - 1.52) 0.49 1.56 (1.12 - 2.19) <0.01
Nodule Size <= 6 mm > 6 mm			1.11(0.79-1.55) 0.54 1.20(0.98-1.49) 0.09
Overall	0.50	1.0 1.5 2.0 OR & 95% Cl	1.18(1.01-1.38) 0.04


Supplementary Figure 2: The cancer hallmarks represented by the 36 informative protein markers, and the corresponding allocation. The fold enrichment is calculated for each hallmark separately, depicted by circle size, and the significance level (-logFDR) is annotated by color gradient.






Supplementary Figure 3: Heatmap of differential gene expressions based on TCGA data comparing lung cancer tissues vs lung normal tissues based on TCGA database by unsupervised hierarchical clustering. (A) Adenocarcinoma (B) Squamous cell carcinoma. This plot includes 35 genes, as TSHB data was not available in TCGA.


(A) Adenocarcinoma lung cancer tissues




(B) Squamous lung cancer tissues



Supplementary Figure 4: The ROC-AUC of the combined model including Brock score and the top 9 circulating protein markers in comparison to the Brock model, overall and in different subgroups by smoking and nodule size.



Supplementary Figure 5: Violin plots of the top circulating protein markers illustrating differential expression of the top protein markers in lung cancer subjects, subjects with benign nodules and subjects with no nodule.



Healthy Control Benign Nodule Control Lung Cancer Case

REFERENCES

1. Tammemagi MC, Schmidt H, Martel S, *et al.* Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. The Lancet. Oncology 2017;18(11):1523-1531.

2. Field JK, Duffy SW, Baldwin DR, *et al.* The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technology Assessment (Winchester, England) 2016;20(40):1-146.

3. Field JK, Duffy SW, Baldwin DR, *et al.* UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016;71(2):161-170.

4. Chung M, Tam K, Wallace C, *et al.* International Early Lung Cancer Action Program: update on lung cancer screening and the management of CT screen-detected findings. AME Medical Journal 2017;2(8).

5. Menezes RJ, Roberts HC, Paul NS, *et al.* Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. Lung Cancer (Amsterdam, Netherlands) 2010;67(2):177-183.

6. Sanchez-Salcedo P, Berto J, de-Torres JP, *et al.* Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP). Archivos De Bronconeumologia 2015;51(4):169-176.

7. The Human Protein Atlas. *The Human Protein Atlas*. <u>https://www.proteinatlas.org/</u> (May 31, 2022; date last accessed).

8. Schmidt T, Samaras P, Frejno M, *et al.* ProteomicsDB. Nucleic Acids Res 2018;46(D1):D1271d1281.

9. Samaras P, Schmidt T, Frejno M, *et al.* ProteomicsDB: a multi-omics and multi-organism resource for life science research. Nucleic Acids Research 2020;48(D1):D1153-D1163.

10. ProteomicsDB. ProteomicsDB. 2021, <u>https://www.proteomicsdb.org/</u>.